Malignant glioma: Who benefits from adjuvant chemotherapy?

Lisa M. DeAngelis, Peter C. Burger, Sylvan B. Green, J. Gregory Cairncross

Research output: Contribution to journalArticlepeer-review

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

Original languageEnglish (US)
Pages (from-to)691-695
Number of pages5
JournalAnnals of neurology
Volume44
Issue number4
DOIs
StatePublished - Oct 1 1998

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Malignant glioma: Who benefits from adjuvant chemotherapy?'. Together they form a unique fingerprint.

Cite this